EGFR and non-small cell lung carcinoma: However, no statistically significant OS advantage was observed for ICI treatment versus chemotherapy (HR = 0.97, P = 0.83).<h4>Conclusion</h4>For EGFR-TKI-resistant, L858R-mutated NSCLC, ICI monotherapy appears ineffective.